CHKA and hepatocellular carcinoma: The pooled analysis (using a fixed-effects model) suggested that CKI combined with TACE therapy significantly improved CP improvement compared to TACE alone in the treatment of unresectable HCC (OR = 1.81, 95% CI: 1.08, 3.03; P = 0.02).